Glutamate carboxypeptidase II (GCPII) is an important target for therapeutic and diagnostic interventions aimed at prostate cancer and neurologic disorders. Here we describe the development and optimization of a high-throughput screening (HTS) assay based on fluorescence polarization (FP) that facilitates the identification of novel scaffolds inhibiting GCPII. First, we designed and synthesized a fluorescence probe based on a urea-based inhibitory scaffold covalently linked to a Bodipy TMR fluorophore (TMRGlu). Next, we established and optimized conditions suitable for HTS and evaluated the assay robustness by testing the influence of a variety of physicochemical parameters (e.g., pH, temperature, time) and additives. Using known GCPII inhibitors, the FP assay was shown to be comparable to benchmark assays established in the field. Finally, we evaluated the FP assay by HTS of a 20 000-compound library. The novel assay presented here is robust, highly reproducible (Z' = 0.82), inexpensive, and suitable for automation, thus providing an excellent platform for HTS of small-molecule libraries targeting GCPII.

Institute of Biotechnology Academy of Sciences of the Czech Republic Prague Czech Republic

Zobrazit více v PubMed

Barinka C, Rojas C, Slusher B, Pomper M. Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer. Curr Med Chem. 2012;19:856–870. PubMed PMC

Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG. GCPII Imaging and Cancer. Curr Med Chem. 2012;19:1346–1359. PubMed PMC

Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG Peptidase Inhibitors and Their Potential for Diagnosis and Therapy. Nat Rev Drug Discov. 2005;4:1015–1026. PubMed

Marmiroli P, Slusher B, Cavaletti G. Tissue Distribution of Glutamate Carboxypeptidase II (GCPII) with a Focus on the Central and Peripheral Nervous System. Curr Med Chem. 2012 PubMed

Rovenska M, Hlouchova K, Sacha P, Mlcochova P, Horak V, Zamecnik J, Barinka C, Konvalinka J. Tissue Expression and Enzymologic Characterization of Human Prostate Specific Membrane Antigen and Its Rat and Pig Orthologs. Prostate. 2008;68:171–182. PubMed

Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlcochova P, Hilgert I, Eckschlager T, Konvalinka J. Expression of Glutamate Carboxypeptidase II in Human Brain. Neuroscience. 2007;144:1361–1372. PubMed

Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A Dual-Monoclonal Sandwich Assay for Prostate-Specific Membrane Antigen: Levels in Tissues, Seminal Fluid and Urine. Prostate. 2000;43:150–157. PubMed

Wozniak KM, Rojas C, Wu Y, Slusher BS. The Role of Glutamate Signaling in Pain Processes and Its Regulation by GCP II Inhibition. Curr Med Chem. 2012;19:1323–1334. PubMed

Rahn KA, Slusher BS, Kaplin AI. Glutamate in CNS Neurodegeneration and Cognition and Its Regulation by GCPII Inhibition. Curr Med Chem. 2012;19:1335–1345. PubMed

Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu XC, et al. Selective Inhibition of NAALADase, Which Converts NAAG to Glutamate, Reduces Ischemic Brain Injury. Nat Med. 1999;5:1396–1402. PubMed

Bander NH. Technology Insight: Monoclonal Antibody Imaging of Prostate Cancer. Nat Clin Pract Urol. 2006;3:216–225. PubMed

Ferraris DV, Shukla K, Tsukamoto T. Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors. Curr Med Chem. 2012;19:1282–1294. PubMed

Tsukamoto T, Wozniak KM, Slusher BS. Progress in the Discovery and Development of Glutamate Carboxypeptidase II Inhibitors. Drug Discov Today. 2007;12:767–776. PubMed

Robinson MB, Blakely RD, Couto R, Coyle JT. Hydrolysis of the Brain Dipeptide N-acetyl-L-aspartyl-L-glutamate: Identification and Characterization of a Novel N-acetylated Alpha-Linked Acidic Dipeptidase Activity from Rat Brain. J Biol Chem. 1987;262:14498–14506. PubMed

Rojas C, Frazier ST, Flanary J, Slusher BS. Kinetics and Inhibition of Glutamate Carboxypeptidase II Using a Microplate Assay. Anal Biochem. 2002;310:50–54. PubMed

Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, et al. Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer. J Med Chem. 2008;51:7933–7943. PubMed PMC

Plechanovova A, Byun Y, Alquicer G, Skultetyova L, Mlcochova P, Nemcova A, Kim HJ, Navratil M, Mease R, Lubkowski J, et al. Novel Substrate-Based Inhibitors of Human Glutamate Carboxypeptidase II with Enhanced Lipophilicity. J Med Chem. 2011;54:7535–7546. PubMed PMC

Anderson MO, Wu LY, Santiago NM, Moser JM, Rowley JA, Bolstad ES, Berkman CE. Substrate Specificity of Prostate-Specific Membrane Antigen. Bioorg Med Chem. 2007;15:6678–6686. PubMed PMC

Kamga I, Ng R, Hosaka M, Berkman CE. High-Performance Liquid Chromatography Method for Detecting Prostate-Specific Membrane Antigen Activity. Anal Biochem. 2002;310:125–127. PubMed

Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS, Konvalinka J. Substrate Specificity, Inhibition and Enzymological Analysis of Recombinant Human Glutamate Carboxypeptidase II. J Neurochem. 2002;80:477–487. PubMed

Jameson DM, Croney JC. Fluorescence Polarization: Past, Present and Future. Comb Chem High Throughput Screen. 2003;6:167–173. PubMed

Barinka C, Mlcochova P, Sacha P, Hilgert I, Majer P, Slusher BS, Horejsi V, Konvalinka J. Amino Acids at the N- and C-termini of Human Glutamate Carboxypeptidase II Are Required for Enzymatic Activity and Proper Folding. Eur J Biochem. 2004;271:2782–2790. PubMed

Brideau C, Gunter B, Pikounis B, Liaw A. Improved Statistical Methods for Hit Selection in High-Throughput Screening. J Biomol Screen. 2003;8:634–647. PubMed

Kozikowski AP, Nan F, Conti P, Zhang J, Ramadan E, Bzdega T, Wroblewska B, Neale JH, Pshenichkin S, Wroblewski JT. Design of Remarkably Simple, yet Potent Urea-Based Inhibitors of Glutamate Carboxypeptidase II (NAALADase) J Med Chem. 2001;44:298–301. PubMed

Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, Kozikowski AP, Mease RC, Pomper MG, Lubkowski J. Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization. J Med Chem. 2008;51:7737–7743. PubMed PMC

Zhang AX, Murelli RP, Barinka C, Michel J, Cocleaza A, Jorgensen WL, Lubkowski J, Spiegel DA. A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules. J Am Chem Soc. 2010;132:12711–12716. PubMed PMC

Pavlicek J, Ptacek J, Barinka C. Glutamate Carboxypeptidase II: An Overview of Structural Studies and Their Importance for Structure-Based Drug Design and Deciphering the Reaction Mechanism of the Enzyme. Curr Med Chem. 2012;19:1300–1309. PubMed

Liu T, Nedrow-Byers JR, Hopkins MR, Berkman CE. Spacer Length Effects on In Vitro Imaging and Surface Accessibility of Fluorescent Inhibitors of Prostate Specific Membrane Antigen. Bioorg Med Chem Lett. 2011;21:7013–7016. PubMed PMC

Hlouchova K, Barinka C, Klusak V, Sacha P, Mlcochova P, Majer P, Rulisek L, Konvalinka J. Biochemical Characterization of Human Glutamate Carboxypeptidase III. J Neurochem. 2007;101:682–696. PubMed

Roehrl MH, Wang JY, Wagner G. A General Framework for Development and Data Analysis of Competitive High-Throughput Screens for Small-Molecule Inhibitors of Protein-Protein Interactions by Fluorescence Polarization. Biochemistry. 2004;43:16056–16066. PubMed

Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 1999;4:67–73. PubMed

The calcium-binding site of human glutamate carboxypeptidase II is critical for dimerization, thermal stability, and enzymatic activity

Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II